+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of VIM0423, an oral medication, in adults with isolated dystonia affecting two or more body regions. This rare movement disorder causes sustained muscle contractions leading to abnormal and sometimes twisting movements or postures. The study aims to determine if VIM0423 improves dystonia symptoms compared to a placebo, and if it can enhance daily function and quality of life. Participants will be randomly assigned to receive either VIM0423 or a matching placebo, taking up to six pills each evening before bed for 16 weeks. This Phase 2, double-blind, placebo-controlled trial includes a dose titration, maintenance, and tapering period. The study lasts up to 24 weeks and consists of 6 in-person visits, including screening, baseline assessments, treatment, and safety follow-up. Throughout the study, participants will undergo evaluations such as video assessments of dystonia symptoms, clinical laboratory tests, and EKGs. They will also complete self-assessments regarding the impact of dystonia on daily activities. Researchers will monitor adverse events and measure changes using the Burke-Fahn-Marsden Dystonia Rating Scale and other clinical global impression scales to assess symptom severity and improvements.

Age: 18Years - 70YearsAll GendersPhase 2
45 locations